Report Overview
The Global Neuropathy Screening and Diagnosis Market size was estimated at US$ 4.78 billion in 2025 and is projected to reach US$ 9.15 billion by 2035, growing at a CAGR of 6.7% during the forecast period 2026-2035.
Neuropathy is a condition when nerve damage leads to pain, weakness, numbness, or tingling in one or more parts of one’s body. There is a broad classification in neuropathy and neuropathy can be caused by diabetes, autoimmune diseases, chemotherapy, intake of toxins, etc. The symptoms and treatment depend upon the type of nerves that are being affected.
Some types of neuropathies can be prevented such as neuropathy associated with alcohol abuse or very restrictive diets. Physical trauma is a common cause of injury to the nerves. This can include car accidents, falls, or fractures. Inactivity, or holding still too long in one position, can also cause neuropathy. Increased pressure on the median nerve, a nerve in the wrist that supplies feeling and movement to the hand, causes carpal tunnel syndrome.
Market Scope
| Metrics | Details |
| CAGR | 6.7% |
| Market Size | 2025-2035 |
| Market Estimation Forecast Period | 2026-2035 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Disease Type, Diagnosis Test, and End-User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter's Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers
Increasing prevalence of neuropathy
The demand for the neuropathy screening and diagnosis market is driven by multiple factors. The rising prevalence of various types of neuropathy especially in the older populations propels the market growth.
Furthermore, the demand for neuropathy diagnostics and screening will be fueled by the growing advancements in the field of diagnostics and research. For instance, according to the National Library of Medicine article published in October 2022, around 2.4% of people of the entire global population are affected by peripheral neuropathy. The prevalence of neuropathy has increased to 8% in the older populations.
In epidemiological studies from India from various regions, the overall prevalence of peripheral neuropathy varied from 5 to 2400 per 10,000 population in various community studies. India is composed of a multiethnic, multicultural population who are exposed to different adverse environmental factors such as arsenic and lead. Use of different chemotherapeutic agents with a propensity to affect peripheral nerves, increasing methods of diagnosis of connective tissue disorders, and the use of immunomodulating drugs, the growing aging population is expected to change the spectrum and burden of peripheral neuropathy in the community.
Prevalence of neuropathy in diabetic patients ranges from around 10.5% to 32.2% in various studies across India and up to 50% of patients will eventually develop neuropathy during their disease according to Western literature.
Restraints
Factors such as high cost associated with the screening and diagnostic techniques, lack of awareness among people, and stringent regulatory compliance are expected to hamper the market.
Market Segment Analysis
The neuropathy screening and diagnosis market is segmented based on disease type, diagnosis test, end-user, and region.
Electromyography (EMG) is a diagnostic technique used to assess the health of muscles and the nerve cells that control them (motor neurons). EMG is primarily used to diagnose muscle and nerve disorders. It measures the electrical activity of muscles both at rest and during contraction. During an EMG, small needles (electrodes) are inserted into the muscles being tested. These electrodes detect the electrical activity generated by muscle cells when they contract.
EMG is highly accurate in detecting abnormal electrical activity in muscles and nerves. Specific values may vary depending on the condition being tested, but EMG is generally considered sensitive and specific for diagnosing neuromuscular disorders. EMG is also used in research settings to study muscle function, fatigue, and performance. It informs treatment plans, such as for physical therapy or surgical interventions.
EMG is generally considered safe when performed by trained professionals. Risks include minor discomfort, bleeding, or infection at the needle insertion site. Advances in technology continue to improve EMG accuracy and reduce patient discomfort, such as the development of wireless and miniaturized electrodes.
For instance, in January 2024, a collaborative research team headed by Professors Jae-Woong Jung of the KAIST School of Electrical Engineering (EE) and Jung Kim of the KAIST Department of Mechanical Engineering (ME) announced that they had effectively created a stretchable and adhesive microneedle sensor that is capable of high-level electrical physiological signal detection that is independent of the user’s skin condition.
Market Geographical Share
North America region is expected to hold the largest market share over the forecast period. The rising incidence of neuropathy, growing awareness among people, and the presence of major players in this region help to propel the market.
According to Yale Medicine.org, more than 20 million Americans are being affected by neuropathy. In this region increase in diabetic cases is also one of the reasons for the cause of diabetic neuropathy which is one of the major types of neuropathy. People having autoimmune diseases and cancer are also affected by neuropathy in some cases.
It is also estimated that 47% of the people having diabetes are being affected by diabetic neuropathy in the US. According to effectivehealthcare.gov, around 9.3% of people are affected by various types of neuropathy in the US. In recent times there have been a lot of advancements in the diagnostic techniques of neuropathy in the US. All these factors together led to North America being accounted for the largest market share over the forecast period.
Market Segmentation
By Disease Type
- Autonomic Neuropathy
- Diabetic Neuropathy
- Peripheral Neuropathy
- Focal Neuropathy
- Poly Neuropathy
By Diagnosis Test
- Sensory Testing
- Nerve Conduction Testing
- Electromyography
- Autonomic Testing
- Skin Biopsy
- MRI Scanning
- Others
By End-User
- Hospitals
- Neurology Clinics
- Academic And Research Centers
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Market Competitive Landscape
The major global players in the neuropathy screening and diagnosis market include Eli Lilly and Company, Reddy’s Laboratories, Pfizer Inc., Cipla, Abbott Laboratories, Lupin Ltd., NeuroBo Pharmaceuticals Inc., NeuroMetrix Inc., Glenmark Pharmaceuticals, Teva Pharmaceutical Industries among others.
Recent Developments in the Neuropathy Screening and Diagnosis Market
- Updated diabetes care standards for 2026: The American Diabetes Association's 2026 Standards of Care emphasize regular assessment for diabetic peripheral neuropathy and annual screening for people with diabetes. The recommendations reinforce the importance of identifying nerve damage and foot ulceration risks before severe complications develop.
- Research compares subjective and objective screening methods: A study published in The International Journal of Lower Extremity Wounds in 2026 compared conventional clinical screening methods with an objective nerve testing device. The work highlights ongoing evaluation of how different approaches identify diabetic peripheral neuropathy in clinical practice.
- Greater attention to early detection: Research published in 2026 examined limitations in current approaches to identifying diabetic peripheral neuropathy at an early stage, including the possibility that small fiber damage may be overlooked by routine examinations. This supports continued investigation into screening methods capable of detecting nerve changes before substantial sensory loss occurs.
- Continued use of accessible clinical screening tools: Official diabetes care recommendations continue to emphasize medical history, sensory assessment, vibration testing and 10 gram monofilament examinations. These methods remain important for identifying people who may need further evaluation or preventive foot care.
Why Purchase the Report?
- To visualize the neuropathy screening and diagnosis market segmentation based on disease type, diagnosis test, end-user, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of neuropathy screening and diagnosis market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in Excel consisting of key products of all the major players.
The neuropathy screening and diagnosis market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
